{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:30:59Z","timestamp":1787009459492,"version":"build-2736575974"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T00:00:00Z","timestamp":1718236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH\/NCI Cancer Center","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Image-guided therapies (IGTs) are commonly used in oncology, but their role in adrenocortical carcinoma (ACC) is not well defined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>A retrospective review of patients with ACC treated with IGTs. We assessed response to therapy using RECIST v1.1, time to next line of systemic therapy, disease control rate (DCR), local tumor progression-free survival (LTPFS), and complications of IGTs (based on the Common Terminology Criteria for Adverse Events [CTCAE] version 5.0).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our cohort included 26 patients (median age 56 years [range 38-76]; n\u2005=\u200518 female) who had 51 IGT sessions to treat 86 lesions. IGTs modalities included cryoablation (n\u2005=\u200549), microwave ablation (n\u2005=\u200521), combined microwave and bland trans-arterial embolization (n\u2005=\u20058), bland trans-arterial embolization alone (n\u2005=\u20053), radio-embolization (n\u2005=\u20053), and radiofrequency ablation (n\u2005=\u20052). DCR was 81.4% (70 out of 86), of which 66.3% of tumors showed complete response, 18.6% showed progressive disease, 8.1% showed partial response, and 7.0% showed stable disease. LTPFS rates were 73% and 63% at 1 and 2 years, respectively. Fourteen lesions underwent re-ablation for incomplete response on initial treatment. Sixteen patients (61.5%) received new systemic therapy following IGTs, with a median time to systemic therapy of 12.5 months (95% CI: 8.6 months upper limit not reached). There was 1 reported CTCAE grade 3 adverse event (biloma) following IGT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>IGT use in properly selected patients with ACC is safe and associated with prolonged disease control and delay in the need for systemic therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyae130","type":"journal-article","created":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T17:06:54Z","timestamp":1715965614000},"page":"850-858","source":"Crossref","is-referenced-by-count":7,"title":["Clinical outcomes of image-guided therapies in patients with adrenocortical carcinoma: a tertiary referral center retrospective study"],"prefix":"10.1093","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0564-1953","authenticated-orcid":false,"given":"Brenda","family":"Chahla","sequence":"first","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center , Houston, TX ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0777-2260","authenticated-orcid":false,"given":"Koustav","family":"Pal","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center , Houston, TX ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vania","family":"Balderrama-Brondani","sequence":"additional","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center , Houston, TX ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feyza","family":"Yaylaci","sequence":"additional","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center , Houston, TX ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew T","family":"Campbell","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center , Houston, TX ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9615-8985","authenticated-orcid":false,"given":"Rahul A","family":"Sheth","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center , Houston, TX ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4148-9637","authenticated-orcid":false,"given":"Mouhammed Amir","family":"Habra","sequence":"additional","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center , Houston, TX ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,6,13]]},"reference":[{"issue":"11","key":"2024100317291610800_CIT0001","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1002\/cncr.23886","article-title":"Adrenocortical carcinoma in the United States","volume":"113","author":"Bilimoria","year":"2008","journal-title":"Cancer"},{"issue":"11","key":"2024100317291610800_CIT0002","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.4158\/DSCR-2020-0567","article-title":"American association of clinical endocrinology disease state clinical review on the evaluation and management of adrenocortical carcinoma in an adult: a practical approach","volume":"26","author":"Kiseljak-Vassiliades","year":"2020","journal-title":"Endocr Pract"},{"issue":"7","key":"2024100317291610800_CIT0003","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1002\/cam4.3740","article-title":"Long-term outcomes in patients with advanced adrenocortical carcinoma after image-guided locoregional ablation or embolization","volume":"10","author":"Mauda-Havakuk","year":"2021","journal-title":"Cancer Med"},{"issue":"5","key":"2024100317291610800_CIT0004","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1210\/clinem\/dgac046","article-title":"Temporal trends in outcomes in patients with adrenocortical carcinoma: a multidisciplinary referral-center experience","volume":"107","author":"Daher","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2024100317291610800_CIT0005","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European society of endocrinology clinical practice guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors","volume":"179","author":"Fassnacht","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"2-03","key":"2024100317291610800_CIT0006","first-page":"109","article-title":"Advanced adrenocortical carcinoma - what to do when first-line therapy fails","volume":"127","author":"Megerle","year":"2019","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"5","key":"2024100317291610800_CIT0007","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1055\/a-1453-0806","article-title":"Advanced adrenocortical carcinoma: current perspectives on medical treatment","volume":"53","author":"Araujo","year":"2021","journal-title":"Horm Metab Res"},{"issue":"7","key":"2024100317291610800_CIT0008","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1111\/bcp.14721","article-title":"Pharmacological profile and effects of mitotane in adrenocortical carcinoma","volume":"87","author":"Corso","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"2024100317291610800_CIT0009","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11912-019-0773-7","article-title":"Management of adrenocortical carcinoma","volume":"21","author":"Jasim","year":"2019","journal-title":"Curr Oncol Rep"},{"issue":"23","key":"2024100317291610800_CIT0010","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","article-title":"Combination chemotherapy in advanced adrenocortical carcinoma","volume":"366","author":"Fassnacht","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"2024100317291610800_CIT0011","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1055\/a-2209-6022","article-title":"Current evidence on local therapies in advanced adrenocortical carcinoma","volume":"56","author":"Kimpel","year":"2024","journal-title":"Horm Metab Res"},{"issue":"3","key":"2024100317291610800_CIT0012","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/cncr.11084","article-title":"Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases","volume":"97","author":"Wood","year":"2003","journal-title":"Cancer"},{"issue":"4","key":"2024100317291610800_CIT0013","doi-asserted-by":"crossref","first-page":"312","DOI":"10.7326\/0003-4819-133-4-200008150-00028","article-title":"Radiofrequency ablation of metastatic lesions in adrenocortical cancer","volume":"133","author":"Abraham","year":"2000","journal-title":"Ann Intern Med"},{"issue":"11","key":"2024100317291610800_CIT0014","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","article-title":"Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Fassnacht","year":"2020","journal-title":"Ann Oncol"},{"issue":"6","key":"2024100317291610800_CIT0015","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1007\/s00261-020-02848-1","article-title":"Percutaneous cryoablation of adrenal metastases: technical feasibility and safety","volume":"46","author":"Aoun","year":"2021","journal-title":"Abdom Radiol (NY)"},{"issue":"2","key":"2024100317291610800_CIT0016","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"1","key":"2024100317291610800_CIT0017","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1148\/radiol.14132958","article-title":"Image-guided tumor ablation: standardization of terminology and reporting criteria\u2014a 10-year update","volume":"273","author":"Ahmed","year":"2014","journal-title":"Radiology"},{"issue":"3","key":"2024100317291610800_CIT0018","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1148\/radiol.2021203715","article-title":"Consensus guidelines for the definition of time-to-event end points in image-guided tumor ablation: results of the SIO and DATECAN Initiative","volume":"301","author":"Puijk","year":"2021","journal-title":"Radiology"},{"key":"2024100317291610800_CIT0019","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0: Quick Reference","author":"Institute","year":"2017"},{"issue":"5","key":"2024100317291610800_CIT0020","doi-asserted-by":"crossref","first-page":"831","DOI":"10.3390\/diagnostics13050831","article-title":"Subcapsular biloma following endoscopic retrograde cholangiopancreatography and endoscopic biliary sphincterotomy: a case report with a mini review of literature","volume":"13","author":"Pentara","year":"2023","journal-title":"Diagnostics"},{"issue":"7","key":"2024100317291610800_CIT0021","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1007\/s00261-020-02947-z","article-title":"MRI evaluation of bile duct injuries and other post-cholecystectomy complications","volume":"46","author":"Reddy","year":"2021","journal-title":"Abdominal Radiology"},{"issue":"12","key":"2024100317291610800_CIT0022","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1007\/s00330-020-07019-w","article-title":"Oligometastatic adrenocortical carcinoma: the role of image-guided thermal ablation","volume":"30","author":"Veltri","year":"2020","journal-title":"Eur Radiol"},{"issue":"10","key":"2024100317291610800_CIT0023","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.jvir.2010.05.020","article-title":"Transcatheter arterial chemoembolization for liver metastases in patients with adrenocortical carcinoma","volume":"21","author":"Cazejust","year":"2010","journal-title":"J Vasc Interv Radiol"},{"issue":"11","key":"2024100317291610800_CIT0024","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.3390\/cancers14112730","article-title":"Loco-regional therapies in oligometastatic adrenocortical carcinoma","volume":"14","author":"Roux","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2024100317291610800_CIT0025","doi-asserted-by":"crossref","first-page":"613248","DOI":"10.3389\/fendo.2021.613248","article-title":"Current status and future targeted therapy in adrenocortical cancer","volume":"12","author":"Alyateem","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"2024100317291610800_CIT0026","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2217\/ije.14.13","article-title":"Emerging therapy for adrenocortical carcinoma","volume":"1","author":"Aufforth","year":"2014","journal-title":"Int J Endocr Oncol"},{"issue":"2","key":"2024100317291610800_CIT0027","first-page":"62","article-title":"Role of mitotane in adrenocortical carcinoma - review and state of the art","volume":"14","author":"Paragliola","year":"2018","journal-title":"Eur Endocrinol"},{"issue":"3","key":"2024100317291610800_CIT0028","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1677\/erc.1.01029","article-title":"Management of patients with adrenal cancer: recommendations of an international consensus conference","volume":"12","author":"Schteingart","year":"2005","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"2024100317291610800_CIT0029","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1530\/EJE-13-0519","article-title":"Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center","volume":"169","author":"Ayala-Ramirez","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2024100317291610800_CIT0030","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00000658-199909000-00004","article-title":"Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases","volume":"230","author":"Fong","year":"1999","journal-title":"Ann Surg"},{"issue":"1","key":"2024100317291610800_CIT0031","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000358750","article-title":"Oligometastatic breast cancer: a shift from palliative to potentially curative treatment","volume":"9","author":"Di Lascio","year":"2014","journal-title":"Breast Care"},{"issue":"8","key":"2024100317291610800_CIT0032","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1177\/0141076818763334","article-title":"Thoracic intervention and surgery to cure lung cancer: an overview of stereotactic ablative radiotherapy in early and oligometastatic lung cancer","volume":"112","author":"Chia","year":"2019","journal-title":"J R Soc Med"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/10\/850\/59558351\/oyae130.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/10\/850\/59558351\/oyae130.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T13:34:34Z","timestamp":1727962474000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/29\/10\/850\/7692857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,13]]},"references-count":32,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,6,13]]},"published-print":{"date-parts":[[2024,10,3]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae130","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,6,13]]}}}